Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.

The objectives of the trial are: (i) to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and (ii) to evaluate this combination further for safety and efficacy in a larger cohort of patients. Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. Cytarabine will be administered as a continuous infusion of 100 mg/m2/day for 7 days. In the Phase I portion of the study, dose escalation will be done in cohorts of at least 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study.

Ann Cahill, Vice President, Clinical Development, commented, "It is important for us to continue to study Cloretazine(R) (VNP40101M) in combination with different doses and schedules of cytarabine, the most widely used drug in the treatment of AML. In addition, we want to evaluate Cloretazine(R) (VNP40101M) in a broader group of elderly patients than are currently being studied in our pivotal tri
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... and Company (NYSE: LLY ) announced that it ... (PAF). The donation will enable expansion of the foundation,s patient ... in support of a new fund for patients with nonsquamous ... lung cancer.   PAF is a national, non-profit ...
... July 13, 2011 Reportlinker.com announces that ... in its catalogue: Pharmaceutical ... http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali ... affect those activities? How ...
Cached Medicine Technology:Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer 2Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 2Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 4Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 5Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 6Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 7Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 8Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 9Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 10Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 11Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 12Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 13
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... Hartford, CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil ... 2,175 mile trek of the Appalachian Trail by stepping off Springer Mountain and ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
Breaking Medicine News(10 mins):Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... of the disease , , THURSDAY, Jan. 31 (HealthDay News) ... with severe and non-severe asthma, something that could help ... to treatment. , The study, from the Severe Asthma ... asthma and 382 people with mild or moderate asthma. ...
... Corporation (NYSE: HMN ) will release its fourth ... market closes. The,earnings press release will be available shortly ... at http://www.horacemann.com .,Management will host a conference call ... at 10:00 a.m. ET., The call will be ...
... Jan. 31 MedWaves, Inc. announces the receipt,of ... System for general surgery use for the coagulation ... of a microwave generator,and single patient use sterile ... of a product portfolio and indications for use ...
... Jan. 31 Wild Child, an Australian-based,natural health care ... family products containing only natural or nature identical ingredients,announced ... be available in,44 states across the United States through ... and CEO Leanne Preston said the agreement was the,result ...
... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
Cached Medicine News:Health News:Severe Asthma Unlike Mild Asthma 2Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2Health News:MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: